San Francisco, CA, United States of America

Frederic Waldman

USPTO Granted Patents = 19 (Patent Applications = 7)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 5.1

ph-index = 8

Forward Citations = 512(Granted Patents)

Location History:

San Francisco, CA (US) (1997 - 2011)
San Juan Capistrano, CA (US) (2018 - 2024)

Company Filing History:

12 out of 15,475

University of California

patents

7 out of 479

Quest Diagnostics Investments, Inc.

patents

1 out of 9

Clinical Genomics Pty. Ltd.

patents

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12264357 - Universal Sanger sequencing from next-gen sequencing amplicons (2025-04-01),

2. 11981966 - Methods for screening solid tumors for mutations (2024-05-14),

3. 11486007 - Methylated markers for colorectal cancer (2022-11-01),

4. 11085079 - Universal Sanger sequencing from next-gen sequencing amplicons (2021-08-10),

5. 11053542 - Compositions and methods for screening mutations in thyroid cancer (2021-07-06),

6. 10689710 - Methods for screening solid tumors for mutations (2020-06-23),

7. 10138519 - Universal sanger sequencing from next-gen sequencing amplicons (2018-11-27),

8. 8021837 - Detection of chromosomal abnormalities associated with breast cancer (2011-09-20),

9. 7537895 - Comparative genomic hybridization (2009-05-26),

10. 7534567 - Detection of nucleic acid sequence differences by comparative genomic hybridization (2009-05-19),

11. 7238484 - Comparative genomic hybridization (2007-07-03),

12. 7094534 - Detection of chromosoal abnormalities associated with breast cancer (2006-08-22),

13. 6335167 - Comparative genomic hybridization (CGH) (2002-01-01),

14. 6159685 - Comparative genomic hybridization (2000-12-11),

15. 615968 - Comparative genomic hybridization (2000-12-12),

Title: Frederic Waldman: Innovating Cancer Treatment Methods

Introduction: Frederic Waldman, a talented inventor based in San Juan Capistrano, CA, has made significant contributions to the field of healthcare with his groundbreaking patent on screening solid tumors for mutations.

Latest Patents: Frederic Waldman's notable patent is on "Methods for screening solid tumors for mutations," revolutionizing the process of determining the efficacy of treatment for breast cancer, colorectal cancer, melanoma, and lung cancer. By detecting alterations in specific cancer-related genes, these methods guide personalized therapeutic decisions for patients.

Career Highlights: Waldman is associated with Quest Diagnostics Investments, Inc., a renowned company in the healthcare industry. His expertise and dedication have propelled him to the forefront of cancer research, striving to improve patient outcomes and advance medical technology.

Collaborations: Frederic has worked closely with his coworker, Kevin Qu, to further refine and implement his innovative screening methods. Together, they harness their collective knowledge and skills to develop cutting-edge solutions in the fight against cancer.

Conclusion: Frederic Waldman's pioneering work in cancer diagnostics stands as a testament to his passion for innovation and commitment to enhancing healthcare practices. His collaboration with industry leaders like Quest Diagnostics Investments, Inc., and coworker Kevin Qu, underscores his drive to make a meaningful impact on the lives of cancer patients worldwide.

This text is generated by artificial intelligence and may not be accurate.